Publications by authors named "An-Shan Wu"
Front Med (Lausanne)
March 2022
Article Synopsis
- A study assessed the effectiveness of neoadjuvant chemotherapy with bevacizumab (TCB) versus standard chemotherapy (TC) in patients with advanced ovarian cancer.
- *The TCB regimen significantly lowered cancer marker CA125 levels and ascites volume, leading to less intraoperative blood loss and shorter surgery times, along with higher surgical satisfaction rates.
- *Overall, TCB was found to be more effective than TC alone, showing potential for better patient outcomes and fewer postoperative complications.
